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Speech communication under adverse conditions (Mattys et al., 2012; Marsh et al., 2015) requires
the interaction of hearing with cognition, upon which the new cognitive hearing science centers
(Arlinger et al., 2009). Adverse conditions affecting speech communication include cognitive
impairments (Mattys et al., 2012), which could relate to age- and disease-related cholinergic
decline (Zubieta et al., 2001; Terry and Buccafusco, 2003). Such declines concern the role of
the ligand acetylcholine in the transfer of information within the brain. Cholinergic decline is
more of a consequence than a cause of Alzheimer’s dementia. The cause is neurodegeneration
via complex mechanisms with underpinnings in multiple genomic, proteomic, and metabolomic
cascades (Cacabelos, 2007). However, in palliative treatment, clinical doses of drugs known as
acetylcholinesterase inhibitors, including Donepezil (Cacabelos, 2007), can delay the progression
of the cognitive symptoms of Alzheimer’s dementia by a matter of months (Francis et al., 1999).
These drugs can improve the ease and efficiency by which cognitive working memory operates
(Furey et al., 1997). Working memory arguably supports the storage of contextual information
necessary for perceptual decision-making during the concurrent processing of speech information
that is obscured or degraded.
Hardy et al.’s recent approach to degrading such information is to use sinewave speech:
Sinusoids, which follow the center frequencies of the original utterance’s formants, trace onlymodes
of the supralaryngeal vocal tract resonant frequency (Remez et al., 1981). Such sinewave replicas
exclude all other speech information. Prior to Hardy et al.’s investigation, it remained unknown
whether enhanced acetylcholine transmission would improve the top-down perception of degraded
speech. In persons with Alzheimer’s dementia, using Donepezil, Hardy et al. showed exactly that.
Vesicles of the neurotransmitter acetylcholine convey information from neuron-to-neuron
(Figure 1A). Reductions in the number of such vesicles can impair that informational transfer
(Figure 1B). Acetylcholinesterase is an enzyme catalytic to the neurotransmitter’s hydrolysis
(Figure 1C). Acetylcholinesterase inhibitors, such as Donepezil, are drugs that reduce the rate of
this breakdown by biochemically interfering with acetylcholinesterase’s action (Figure 1D). The
consequence is slow hydrolysis (Figure 1E). A nervous system with acetylcholine shortage exhibits
suboptimal synaptic signaling between neurons (Figure 1B). Acetylcholinesterase inhibitors thus
offer systemic control of acetylcholine levels (Figure 1D).
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Hardy et al. presented persons with Alzheimer’s disease
and healthy elderly control adults with either clear speech
or sinewave replicas. These stimuli were 3-digit lists such as
“eight hundred and eighty-seven” (Figure 1F). To-be-attended
speech information was not obscured by to-be-ignored sound,
as occurs with speech in noise. Rather, in such sinewave replicas
this speech information was instead degraded. At first, most
listeners perceive those degraded speech-derived replicas as
pitch-varying whistles. However, after some exposure, a top-
down insight occurs: The listener starts to hear the message as
speech.
Having Alzheimer’s disease hampers perception of the
degraded sinewave speech (Figure 1G cf. Figure 1I) yet not the
clear speech. Both during a first baseline session and during
a second listening, whistles become more speech-like: Both
groups show improvements in degraded speech perception
within each session (Figures 1G–J). However, administering
Donepezil between sessions to persons with Alzheimer’s disease
further improves degraded speech perception (Figures 1G, H).
Enhanced acetylcholine neurotransmission thus seems to
improve this perception of degraded speech for persons
with Alzheimer’s disease whom tend to have disease-related
cholinergic abnormalities. Comparable effects do not generalize
to other cognitive tasks, so Donepezil affects neurocognitive
mechanisms closely allied to speech perception.
An extant cognitive hearing science account of the influence of
selective auditory attention on speech perception under adverse
conditions adopts a cholinergic top-down control assumption
(Marsh and Campbell, 2016) with which Hardy et al.’s drug effect
harmonizes: The limited set of possible three-digit utterances
promotes top-down processing. This processing uses the stored
memory of the immediately preceding acoustical context during
the concurrent proactive prediction of the utterance. That
processing also uses the stored memory of information gathered
in favor of lexical candidates to retroactively repair perceptual
decisions. The concurrent processing during the storage of these
memories is a working memory function. Acetylcholinesterase
inhibition can improve processing efficiency: Physostigmine
not only reduces the effort required to perform a working
memory task but also the regional cerebral bloodflow in the right
prefrontal cortex (Furey et al., 1997). With Donepezil, treating
cholinergic abnormalities, theoretically, the prefrontal cortex of
the cortical cholinergic attentional system (Sarter et al., 2005)
better controls the auditory cortex. Such top-down control takes
place via the cholinergic basal forebrain enhancing degraded
speech perception.
An unexplored corollary of this cholinergic top-down
control assumption is that the cholinergic cortical attentional
system, including the prefrontal cortices, controls an
early filter (Sarter et al., 2005; Marsh and Campbell, 2016).
Accordingly, prefrontal control of loops of the brain’s interacting
ascending and descending auditory systems realize this filter.
A top-down modulation affects structures of the rostral
brainstem early on within the bottom-up ascension of auditory
information (Figure 1K). Mild cognitive impairment causes
abnormalities in the auditory responses of the human rostral
brainstem, which could reflect initial signs of conversion
to Alzheimer’s disease (Bidelman et al., 2017). An untested
prediction is thus that pharmacological manipulations of top-
down cholinergic mechanisms would affect subcortical speech
processing.
Hardy et al.’s findings thus unleash the potential of a
new cognitive hearing science. This science could establish
how acetylcholine affects speech-in-noise performance in
persons with hearing or cognitive impairments: Empirically
undetermined is whether Hardy et al.’s cholinergic influence
confines to a top-down focusing of the listening to attended
speech information; be that signal degraded or obscured.
During speech-in-noise perception and understanding, another
cholinergic influence may also be upon the top-down selective
inhibition of ascending to-be-ignored noise (Petersen et al.,
2017). Uninhibited, such noise arguably causes distraction by
diverting a prefrontal capacity limitation (Marsh and Campbell,
2016) away from the to-be-attended speech information that the
noise also masks.
Some sobering words of caution are necessary: Without
the design administering Donepezil to healthy controls,
a question germane to the cholinergic top-down control
assumption goes unaddressed. Could there be a cholinergic
influence on speech perception in persons without Alzheimer’s
Disease? Hardy et al. do provide normative data that tend
toward ceiling (Figure 1J), in which performance on a more
demanding speech perception task, or pupillometry, may
prove even more revealing (Wendt et al., 2017) administering
Donepezil to such healthy elderly persons. A design with an
additional placebo-controlled arm would also better substantiate
Donepezil’s influence on speech perception (Hardy et al.,
2017), were the drug effect to replicate with a significantly
stronger between-sessions improvement than in a placebo-
control arm. Further, different acetylcholinesterase inhibitors
show different affinities for and selectivity to acetylcholine,
yet remain about as therapeutically effective (Cacabelos,
2007). Different acetylcholinesterase inhibitors thus have
distinct collateral mechanisms of action that are indirectly
related, or even unrelated, to cholinergic neurotransmission.
Whether some such collateral mechanisms mediate Hardy
et al.’s effect of Donepezil remains unknown: Experimental
comparisons with different acetylcholinesterase inhibitors are
lacking.
Turning from theoretical caution to conservative assays of
clinical potential, a subtle breakdown of the brain’s network for
language comprehension predicts the conversion of individuals
with mild cognitive impairment into persons with Alzheimer’s
disease (Mazaheri et al., 2018). Regular activity of this language
comprehension system may thus be paramount. Germane is
that having hearing loss associates with increased risk of
dementia (Lin et al., 2011). Hearing aid use eliminates this
association (Amieva et al., 2018). Using Donepezil associates with
reduced mortality for nursing home residents with dementia
(Gasper et al., 2005). Contrastingly, chronic administration of
another acetylcholinesterase inhibitor, Galantamine, increases
mortality (Kirshner, 2005). Given the known side effects
(Kirshner, 2005), for Donepezil to become a viable treatment
for cognitive difficulties with speech intelligibility under
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FIGURE 1 | Theory of how acetylcholinesterase improves intelligibility of sinewave speech in persons with Alzheimer’s dementia. Cholinergic neurotransmission
(A) can exhibit age- or disease-related abnormalities with consequences for neurotransmission including impaired acetylcholine release (B). This impairment
yields less acetate for presynaptic high-affinity choline transporters to supply intracellular synthesis of the acetylcholine ligand (ACh) for packaging into vesicles
to release into the synaptic cleft (B). In turn, there are fewer such vesicles of acetylcholine to bind to postsynaptic muscarinic receptors (B). Binding to
muscarinic receptors indirectly increases intracellular Ca+ levels initiating a postsynaptic action potential (A) that does not occur with fewer vesicles and thus
less such binding (B). A distinct mechanism to initiate action potentials relies on the binding of ACh to nicotinic acetylcholine receptors permitting the influx of
extracellular Ca+. This neurotransmitter ACh undergoes a fast hydrolysis that the macromolecule acetylcholinesterase (AChE) rapidly catalyzes into choline and
acetic acid (C) that yields acetate ions in extracellular equilibrium (A,B). The acetylcholinesterase inhibitor Donepezil forms an AChE-Donepezil complex (D)
blocking gorges in AChE macromolecules containing the illustrated active anionic and esteric sites to which ACh would otherwise bind during fast hydrolysis (C).
(Continued)
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FIGURE 1 | This acetylcholinesterase inhibition in turn can upregulate impaired cholinergic neurotransmission (D) by slowing hydrolysis (E). The perception of
sinewave speech (F) improves during a session (G,H) from baseline levels (G) following a clinical dose of Donepezil (H) for persons with Alzheimer’s dementia. The
extent of this drug effect exceeds any null influence of practice across successive sessions for their age-matched controls (I,J). The interpretation offered (K) is that
the prefrontal cortex of the cortical cholinergic attentional system improves the otherwise impaired control of the auditory cortex via the cholinergic basal forebrain.
Theoretically, the basal forebrain top-down controls an early filter, which affects speech perception within loops of the brain’s interacting ascending and descending
auditory systems including the rostral brainstem (F–H). Credits: Copyright 2017 by CDC Global (https://flic.kr/ps/2mHk9t2mHk9t2mHk9t2mHk9t). Reprinted courtesy
of Hardy et al. under a Creative Commons License CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).
adverse conditions, there thus remain objectives for responsible
clinical research: Without any chronic administration increasing
mortality risk, long-term effects on intelligibility should be
shown that eliminate longitudinal associations between hearing
loss and the subsequent incidence or progress of Alzheimer’s
disease.
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